Seppo Ylä-Herttuala Selected Research

Vascular Endothelial Growth Factor Receptor-3 (Flt 4)

6/2015	Growth factor therapy and lymph node graft for lymphedema.
3/2013	Preclinical safety, toxicology, and biodistribution study of adenoviral gene therapy with sVEGFR-2 and sVEGFR-3 combined with chemotherapy for ovarian cancer.
1/2013	Neuropilin-2 and vascular endothelial growth factor receptor-3 are up-regulated in human vascular malformations.
11/2012	Critical role of VEGF-C/VEGFR-3 signaling in innate and adaptive immune responses in experimental obliterative bronchiolitis.
11/2010	In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies.
3/2010	Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts.
7/2008	Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.
6/2008	The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
10/2003	Vascular endothelial growth factor-D expression in human atherosclerotic lesions.
7/2002	Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Seppo Ylä-Herttuala Research Topics

Disease

53	Atherosclerosis 01/2022 - 01/2002
49	Neoplasms (Cancer) 10/2021 - 02/2002
38	Inflammation (Inflammations) 01/2022 - 05/2002
24	Glioma (Gliomas) 01/2020 - 03/2002
23	Atherosclerotic Plaque (Atheroma) 01/2021 - 11/2002
18	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 11/2003
16	Hypoxia (Hypoxemia) 01/2022 - 04/2002
13	Ischemia 10/2021 - 04/2002
13	Myocardial Infarction 10/2020 - 11/2005
10	Myocardial Ischemia (Ischemic Heart Diseases) 10/2021 - 06/2003
9	Type 2 Diabetes Mellitus (MODY) 01/2021 - 01/2003
9	Lymphedema (Milroy Disease) 07/2015 - 07/2002
8	Ovarian Neoplasms (Ovarian Cancer) 01/2020 - 12/2010
8	Infections 10/2017 - 03/2003
7	Coronary Artery Disease (Coronary Atherosclerosis) 12/2021 - 06/2011
7	Fibrosis (Cirrhosis) 01/2021 - 02/2012
7	Heart Failure 01/2021 - 01/2011
7	Wounds and Injuries (Trauma) 01/2019 - 11/2004
6	Infarction (Infarctions) 10/2021 - 11/2013
6	Neoplasm Metastasis (Metastasis) 01/2020 - 12/2007
6	Coronary Disease (Coronary Heart Disease) 01/2019 - 06/2003
5	Ovarian Epithelial Carcinoma 01/2020 - 03/2004
5	Insulin Resistance 01/2016 - 01/2003
5	Neointima 01/2016 - 03/2004
5	Carcinoma (Carcinomatosis) 09/2014 - 06/2008
4	Hypercholesterolemia 01/2021 - 01/2019
4	Hemangioma (Angioma) 01/2019 - 01/2013
4	Thrombosis (Thrombus) 01/2018 - 01/2005
4	Edema (Dropsy) 01/2017 - 09/2002
4	Vascular Diseases (Vascular Disease) 03/2014 - 04/2007
4	Cardiomegaly (Heart Hypertrophy) 01/2014 - 10/2008
4	Hypertrophy 12/2012 - 10/2008
3	Hyperlipidemias (Hyperlipidemia) 01/2022 - 07/2015
3	Vascular Remodeling 01/2021 - 10/2013
3	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 01/2021 - 12/2012
3	Glucose Intolerance 01/2021 - 01/2013
3	Pathologic Constriction (Stenosis) 01/2018 - 05/2005
3	Intracranial Aneurysm (Cerebral Aneurysm) 01/2016 - 06/2011
3	Arteriosclerosis 03/2010 - 05/2002
3	Hyperplasia 06/2007 - 03/2004

Drug/Important Bio-Agent (IBA)

47	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 04/2002
20	Proteins (Proteins, Gene)FDA Link 06/2019 - 01/2002
19	LipidsIBA 01/2022 - 03/2003
17	Vascular Endothelial Growth Factor DIBA 01/2021 - 09/2002
15	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 10/2018 - 01/2002
14	Vascular Endothelial Growth Factor CIBA 06/2019 - 07/2002
12	CholesterolIBA 01/2021 - 08/2002
12	Thymidine KinaseIBA 01/2020 - 11/2002
12	Ganciclovir (Cytovene)FDA LinkGeneric 01/2020 - 04/2002
11	Lipoproteins (Lipoprotein)IBA 10/2019 - 08/2002
10	Vascular Endothelial Growth Factor Receptor-3 (Flt 4)IBA 06/2015 - 07/2002
9	AntibodiesIBA 01/2022 - 03/2003
9	Vascular Endothelial Growth Factor BIBA 12/2021 - 08/2005
9	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2003
9	Insulin-Like Growth Factor II (Somatomedin A)IBA 03/2019 - 11/2007
9	LDL Receptors (LDL Receptor)IBA 01/2019 - 08/2005
8	RNA (Ribonucleic Acid)IBA 10/2021 - 04/2013
8	Messenger RNA (mRNA)IBA 10/2021 - 02/2007
8	Transcription Factors (Transcription Factor)IBA 01/2019 - 06/2005
8	Apolipoprotein B-100 (Apo B 100)IBA 01/2019 - 11/2007
7	MicroRNAs (MicroRNA)IBA 01/2022 - 07/2008
7	LigandsIBA 10/2021 - 03/2002
7	Vascular Endothelial Growth FactorsIBA 01/2021 - 05/2006
7	Pharmaceutical PreparationsIBA 01/2021 - 12/2003
7	oxidized low density lipoproteinIBA 03/2019 - 08/2002
7	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 11/2002
7	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 06/2015 - 04/2002
6	CytokinesIBA 02/2016 - 01/2002
6	ApolipoproteinsIBA 02/2016 - 01/2003
5	Therapeutic UsesIBA 10/2021 - 01/2002
5	Angiopoietin-2IBA 01/2020 - 12/2010
5	Apolipoproteins E (ApoE)IBA 01/2019 - 03/2003
5	EnzymesIBA 08/2013 - 11/2003
5	AvidinIBA 12/2012 - 12/2003
4	Peptides (Polypeptides)IBA 10/2021 - 05/2008
4	Biomarkers (Surrogate Marker)IBA 01/2020 - 09/2014
4	ProdrugsIBA 01/2020 - 10/2009
4	Monoclonal AntibodiesIBA 01/2020 - 12/2003
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 06/2019 - 05/2008
4	Small Interfering RNA (siRNA)IBA 01/2019 - 05/2012
4	Triglycerides (Triacylglycerol)IBA 10/2018 - 09/2013
4	NF-kappa B (NF-kB)IBA 07/2012 - 01/2003
3	Biological ProductsIBA 01/2021 - 01/2012
3	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2020 - 02/2006
3	TIE-2 Receptor (Receptor, TIE 2)IBA 01/2020 - 03/2003
3	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 01/2020 - 04/2009
3	AntioxidantsIBA 01/2019 - 08/2002
3	Insulin (Novolin)FDA Link 01/2019 - 01/2003
3	Retinaldehyde (Retinal)IBA 08/2018 - 02/2012
3	Oxygen (Dioxygen)IBA 01/2018 - 11/2003
3	AngiopoietinsIBA 01/2017 - 12/2010
3	HDL CholesterolIBA 12/2012 - 03/2003
3	Biotin (Vitamin H)FDA Link 03/2012 - 03/2002
3	Scavenger Receptors (Scavenger Receptor)IBA 12/2010 - 07/2003

Therapy/Procedure

51	Therapeutics 01/2022 - 04/2002
6	Stents 10/2021 - 06/2003
6	Radiotherapy 06/2015 - 11/2004
3	Photochemotherapy (Photodynamic Therapy) 03/2018 - 02/2011
3	Drug Therapy (Chemotherapy) 01/2017 - 03/2013
3	Surgical Amputation (Amputations) 05/2004 - 04/2002